With advancements in the next five years, refined knowledge of compounds, like EI, may usher in precision therapies for resistant BC, particularly within personalized medicine contexts where patient-specific AR/RUNX1 profiles could guide tailored use of EI or similar natural agents. Here, RUNX1 is linked to breast cancer.